home
Bringing New Horizons to Therapy
Investor Information
Event: November 16, 2011 EDAP TMS is presently accelerating adoption of HIFU therapy as a new standard of care for localized prostate cancer in Europe where the company is the clear market leader while securing US approval through an active FDA Clinical Study at leading urology centers.
Recent Releases
Jan 26, 2012
EDAP Streamlines Capital Structure
Media Coverage
Robotic Ablatherm HIFU's Importance in
Prostate Cancer Surgeries Featured in Major
Conferences
Events & Presentations
Sep 13, 2011 at 10:50 AM ET
Rodman & Renshaw Annual Global Investment Conference
Aug 30, 2011 at 8:30 AM ET
EDAP Second Quarter 2011 Results Conference Call
IR Contact
Stock Information
|
NASDAQ : EDAP Last Price : 2.54 Change : 0.31 10.877%Day High : 2.76 Day Low : 2.45 Year High : 5.02 Year Low : 1.37 Volume : 110,800 |

10.877%